| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 大容量注射液(元) | 3,749,975,809.00 | 8,911,678,039.00 | 4,667,301,102.00 |
| 非大容量注射液(元) | 4,393,945,959.00 | 10,300,327,368.00 | 5,408,989,284.00 |
| 研发项目(元) | 636,852,225.00 | 1,894,758,860.00 | 1,386,877,475.00 |
| 营业成本(元) | |||
| 大容量注射液(元) | 1,646,881,953.00 | 3,550,566,794.00 | 1,761,148,485.00 |
| 非大容量注射液(元) | 2,396,437,408.00 | 5,777,822,294.00 | 3,121,061,955.00 |
| 研发项目(元) | 273,144,978.00 | 653,752,620.00 | 304,183,878.00 |
| 毛利(元) | |||
| 大容量注射液(元) | 2,103,093,856.00 | 5,361,111,245.00 | 2,906,152,617.00 |
| 非大容量注射液(元) | 1,997,508,551.00 | 4,522,505,074.00 | 2,287,927,329.00 |
| 研发项目(元) | 363,707,247.00 | 1,241,006,240.00 | 1,082,693,597.00 |
| 毛利率(%) | |||
| 大容量注射液(%) | 56.08 | 60.16 | 62.27 |
| 非大容量注射液(%) | 45.46 | 43.91 | 42.30 |
| 研发项目(%) | 57.11 | 65.50 | 78.07 |
| 收入构成(%) | |||
| 大容量注射液(%) | 42.71 | 42.22 | 40.72 |
| 非大容量注射液(%) | 50.04 | 48.80 | 47.19 |
| 研发项目(%) | 7.25 | 8.98 | 12.10 |
| 毛利构成(%) | |||
| 大容量注射液(%) | 47.11 | 48.19 | 46.30 |
| 非大容量注射液(%) | 44.74 | 40.65 | 36.45 |
| 研发项目(%) | 8.15 | 11.16 | 17.25 |